Stryker (SYK) Q3 2026 Earnings Call Transcript

Stryker reported Q3 2026 results showing organic sales growth of 7.7% and adjusted EPS of $3.52, up 10.3% year over year. Management attributed the increase to gross margin expansion and operational efficiencies, with adjusted gross margin rising to 65.4% and adjusted operating margin reaching 26.2%. MedSurg and Neurotechnology combined grew organically 9.1%, while Orthopaedics rose 5.9% despite softness in large joint reconstruction and internal execution delays. Endoscopy U.S. sales grew 13%. The company said cash from operations totaled $3.3 billion year to date, up 14%. Full-year organic sales guidance was revised to 6.5%–7.0% and adjusted EPS to $14.80–$14.90; the board authorized an additional $3 billion in buybacks after $1 billion repurchased in Q3.